SS-31
Also known as Elamipretide · Bendavia · MTP-131
New
Reconstitution & dosing guide
10 mg · 50 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
SS·31 (2S10) · Not in current stock
$40 / vial
50mg x 10 vials
SS·31 (2S50) · Not in current stock
$130 / vial
Prices per vial · Research use only · Not medical advice.
Mitochondria-targeting tetrapeptide (elamipretide) studied for bioenergetic and rare disease indications.
How to picture it
Mitochondria have an inner membrane lined with cardiolipin, a special fat that organizes the electron-transport assembly line. SS-31 concentrates inside mitochondria and binds cardiolipin, helping keep that assembly line stable and less leaky of reactive oxygen. Picture a clamp that holds the power plant's conveyor belts in alignment — direct "repair the engine" research when the energy factories themselves are the bottleneck, including cardiac, renal, and aging-mitochondria literature.
Research focus & benefits
- Mitochondrial membrane and cardiolipin stabilization research
- Electron-transport and ROS pathway studies
- Cardiac and renal mitochondria literature
- Clinical development history (elamipretide / Barth syndrome pathway)
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
SS-31 (elamipretide) associates with cardiolipin on the inner mitochondrial membrane and has been evaluated in clinical programs for mitochondrial myopathies, heart failure, and other bioenergetic diseases. Biohackers discuss it as a cellular-energy peptide.
Mechanism
Binds cardiolipin, stabilizing electron transport efficiency and reducing pathological ROS in dysfunctional mitochondria models.
Research uses
- Primary mitochondrial myopathy trials
- Barth syndrome
- Heart failure and reperfusion research
- Age-related mitochondrial dysfunction research
Research dosing notes
Clinical trial and development dosing only for medical contexts; research market is not pharmaceutical grade.
Half-life / kinetics
Short; clinical regimens often daily subcutaneous
Common research routes
Reported considerations
- Injection-site reactions
- Eosinophilia in some studies
- Trial-specific adverse events
Contraindications / cautions
- Follow trial/label constraints
- Pregnancy
- Unverified research vials for serious disease
Common research stacks
- MOTS-c
- Humanin
- Aerobic base training
Legal / access note
Elamipretide has been in clinical development with mixed regulatory outcomes by indication; not a general wellness approved drug for all uses.